Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

Bausch Health Americas, Inc.

Overview

To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Methadone-maintenance Subjects

Interventions

MOA-728DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion: 1. Healthy men or women, aged 18 to 65 years. 2. History of methadone treatment for at least 1 month, at a dose \>=30 and \<=140 mg/day. Exclusion: 1. History or active presence of clinically important medical disease. 2. Allergy to opioids.

Locations (1)

Unnamed facility

Gainesville, Florida, United States

Outcomes

Primary Outcomes

To characterize the pharmacodynamics of single oral doses of MOA-728 compared to a positive control of MOA-728 administered intravenously in subjects on stable methadone maintenance.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.